.23 Nov 2018 18:24
Fundamentals are here solid, not sure how many the seller has left but upside/bounce from here is significant, not often you get these opportunities in AIM - freebies from Lansdowne...
- The ii's buying in well into the £s + directors more recently in the 60s:
- As previously announced, the Board of Imutex is exploring strategic alternatives with regards to both assets, including but not limited to a full sale, a licensing agreement or a non-dilutive funding arrangement with a collaborator to run the Phase III development and study for the FLU-v vaccine candidate. Any material information regarding discussions or about the Imutex assets will be announced as appropriate.
- We anticipate that the majority of the cost savings will not be fully realised until 2019, but we believe that these, along with a healthy project pipeline of client work, will enable the Company to support its business activities with its current cash beyond 2019. Â
-- § Further data analysis and full and final results of FLU-v 004 to be published by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), in due course
- § Publication of the FLU-v 003 full results by Universal Influenza Vaccines Secured Consortium (UNISEC) in due course
The seller has been holding it down ever since the spike to £1 IMO meaning the new contracts/results haven't been priced in yet... when this moves it will move quick